Biocon Integrates Biologics Arm In $5.5 B Deal To Create A Unified Global Biopharma Leader

Biocon Limited has announced that it will fully integrate its subsidiary Biocon Biologics Limited, making it a wholly owned arm of the parent company. This strategic corporate action, formalised on December 6, 2025, aims to unify Biocon’s biosimilars and generics businesses under one umbrella to build a stronger global biopharmaceutical enterprise.

Under the approved plan, Biocon will acquire the remaining shares of Biocon Biologics held by external investors. Shareholders including Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP will exchange their Biologics shares for Biocon shares at a swap ratio of 70.28 Biocon shares for every 100 Biocon Biologics shares. The valuation implied by this exchange places Biocon Biologics at about US $5.5 billion.

Additionally, Biocon will purchase the residual stake held by Mylan (now Viatris) for about US $815 million. This part of the deal includes a cash payment of US $400 million, with the remaining US $415 million settled through another share swap — at a ratio of 61.70 Biocon shares for every 100 Biologics shares, using the same share price benchmark.

To facilitate the cash component of the transaction, Biocon’s board has approved a Qualified Institutional Placement (QIP) to raise up to ₹4,500 crore (≈ US $500 million), pending shareholder approval.

The integration is expected to be completed by March 31, 2026, subject to regulatory and legal approvals. As part of the transition plan, a Governance Council has been constituted under the chairpersonship of Kiran Mazumdar-Shaw, while a Transition and Integration Management Committee, led by Shreehas Tambe — currently CEO & MD of Biocon Biologics — will oversee operational consolidation.

Once integrated, the combined company will strengthen its global position across diabetes, oncology, and immunology — therapeutic areas that together account for nearly 40 percent of global pharmaceutical revenues. With a robust global commercial infrastructure spanning over 120 countries and a unique product portfolio that includes both biosimilar insulins and complex generics such as GLP-1 peptides, Biocon aims to scale its presence in the growing global “diabesity” market.

Also Read